Experience

• 

  Panacor bioscience limited

  Jan 2007 - Dec 2012

  Project manager

  Administer US$3 MM R&D Clinical Program and successfully delivered the Phase III trial. The results achieved all primary and secondary end points.Selected to play the key role in government funding and investor relationship presentation, IPO road show preparation on AIM market (London Stock Exchange), and FDA interaction.

• 

  Panion & bf biotech inc.

  Apr 2013 - May 2015

  Senior project manager

  Led and empowered the team to achieve all regulatory milestones of Nephoxil in Taiwan including NDA, API (Active Pharmaceutical Ingredient) market authorization, API Drug Master File (DMF) approval and API GMP inspection. Collaborated with the team and PIs to successfully publish the PIII Trial on a scientific Journal. Successfully invited world-renowned PIs to join the local marketing campaign and provided speeches in annual Taiwanese Society of Nephrology for Nephoxil for two consecutive years. Show less

• 

  Panion & bf biotech inc

  May 2015 - now

  Director of new drug development division

  Provided leadership for the drug development program covering CMC, clinical, regulatory, business and patent development on Nephoxil, the first small molecule from Taiwan to reach New Drug Approval (NDA) in JP/US/EU.Direct BD activities and global alliance for the lead product which the worldwide revenue will exceed US$100 MM in 2016.Serve as product’s technical spokesman for various events including media relations, investor relations, annual shareholder’s meetings, product launch meetings and symposiums. Serve as a key member of the review board for in/out license of new product pipelines and technologies. Show less

• 

  Weigao panion biotech holding co. ltd (hk)

  Aug 2015 - Apr 2017

  Board of director

  Successfully establish a RMB$150MM strategic joint venture alliance for Panion & BF Biotech with Shang Dong Waigao Pharmaceuticals Co. Ltd for Chinese market.Serve as a board member to provide strategies in product, patent and regulatory developments